about us

ImmunoCellular Therapeutics, Ltd.  is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular’s pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

About Us Collage

Our lead product candidate, ICT-107, has completed a randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial in patients with newly diagnosed glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Results of a phase I study of ICT-107 showed prolonged survival compared with historical controls and minimal side effects. A top-line data read-out from the phase 2 study was reported in December 2013, and updated data from the phase 2 study were reported at the American Society for Clinical Oncology (ASCO) annual meeting in June 2014 and at the Society for Neuro-Oncology (SNO) meeting in November 2014.

In addition to ICT-107, we are developing two other DC vaccines.

ICT-121 is a DC immunotherapy that targets CD133, an antigen commonly associated with CSCs. We are conducting a 20-patient phase 1 clinical trial in patients with recurrent glioblastoma.

ICT-140 is a DC immunotherapy that targets seven different antigens associated with ovarian cancer, including ones expressed by CSCs. We plan to conduct an exploratory phase 2 clinical trial in ovarian cancer. 

Through a licensing agreement with the California Institute of Technology (Caltech), we have exclusive rights to novel technology for the development of certain antigen specific T cell immunotherapies for the treatment of cancer. The technology originated from the labs of David Baltimore, Ph.D., Nobel Laureate and President Emeritus at Caltech, and utilizes the patient’s own hematopoietic stem cells to create antigen-specific killer T cells to treat cancer. We plan to utilize this technology to expand and complement our dendritic cell-based cancer immunotherapy platform, with the goal of developing new immunotherapies that kill cancer cells in a highly directed and specific manner and that can function as monotherapies or in combination therapy approaches.

ImmunoCellular’s goal is to become an industry-leading, independent, commercial-stage cancer immunotherapy company. We have a development pipeline of what we believe are therapeutically important, commercially attractive assets, and a highly productive, proprietary cancer immunotherapy platform that has the potential to transform the treatment of cancer, bring therapeutic benefit to patients and hope to their families, and create value for our stakeholders.

Copyright 2015 by Immunocellular Therapeutics, Ltd.
All Rights Reserved